These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37554099)

  • 1. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny - Part IV: the ECETOC and CLE Proposal for a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS).
    Melching-Kollmuss S; Bothe K; Charlton A; Gangadharan B; Ghaffari R; Jacobi S; Marty S; Marxfeld HA; McInnes EF; Sauer UG; Sheets LP; Strupp C; Tinwell H; Wiemann C; Botham PA; van Ravenzwaay B
    Crit Rev Toxicol; 2023 Jul; 53(6):339-371. PubMed ID: 37554099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny-part III: how is substance-mediated thyroid hormone imbalance in pregnant/lactating rats or their progeny related to neurodevelopmental effects?
    Marty MS; Sauer UG; Charlton A; Ghaffari R; Guignard D; Hallmark N; Hannas BR; Jacobi S; Marxfeld HA; Melching-Kollmuss S; Sheets LP; Urbisch D; Botham PA; van Ravenzwaay B
    Crit Rev Toxicol; 2022 Aug; 52(7):546-617. PubMed ID: 36519295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny - part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?
    Marty S; Beekhuijzen M; Charlton A; Hallmark N; Hannas BR; Jacobi S; Melching-Kollmuss S; Sauer UG; Sheets LP; Strauss V; Urbisch D; Botham PA; van Ravenzwaay B
    Crit Rev Toxicol; 2021 Apr; 51(4):328-358. PubMed ID: 34074207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny - part I: which parameters from human studies are most relevant for toxicological assessments?
    Sauer UG; Asiimwe A; Botham PA; Charlton A; Hallmark N; Jacobi S; Marty S; Melching-Kollmuss S; Palha JA; Strauss V; van Ravenzwaay B; Swaen G
    Crit Rev Toxicol; 2020 Oct; 50(9):740-763. PubMed ID: 33305658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ECETOC Florence workshop on risk assessment of endocrine substances, including the potency concept.
    Fegert I
    Toxicol Lett; 2013 Dec; 223(3):310-4. PubMed ID: 23558296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern.
    Bars R; Fegert I; Gross M; Lewis D; Weltje L; Weyers A; Wheeler JR; Galay-Burgos M
    Regul Toxicol Pharmacol; 2012 Oct; 64(1):143-54. PubMed ID: 22735369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk assessment of 'endocrine substances': guidance on identifying endocrine disruptors.
    Lewis RW
    Toxicol Lett; 2013 Dec; 223(3):287-90. PubMed ID: 24036001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metribuzin-induced non-adverse liver changes result in rodent-specific non-adverse thyroid effects via uridine 5'-diphospho-glucuronosyltransferase (UDPGT, UGT) modulation.
    Bomann W; Tinwell H; Jenkinson P; Kluxen FM
    Regul Toxicol Pharmacol; 2021 Jun; 122():104884. PubMed ID: 33596450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring a mechanism-based approach for the identification of endocrine disruptors using Adverse Outcome Pathways (AOPs) and New Approach Methodologies (NAMs) : A perfluorooctane sulfonic acid case study.
    Wiklund L; Pípal M; Weiss J; Beronius A
    Toxicology; 2024 May; 504():153794. PubMed ID: 38580097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypothesis-driven weight-of-evidence analysis of endocrine disruption potential: a case study with triclosan.
    Mihaich E; Capdevielle M; Urbach-Ross D; Slezak B
    Crit Rev Toxicol; 2017 Apr; 47(4):263-285. PubMed ID: 28128023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Science based guidance for the assessment of endocrine disrupting properties of chemicals.
    Bars R; Broeckaert F; Fegert I; Gross M; Hallmark N; Kedwards T; Lewis D; O'Hagan S; Panter GH; Weltje L; Weyers A; Wheeler JR; Galay-Burgos M
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):37-46. PubMed ID: 20858523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
    Borgert CJ
    Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enhancement of the subacute repeat dose toxicity test OECD TG 407 for the detection of endocrine active chemicals: comparison with toxicity tests of longer duration.
    Gelbke HP; Hofmann A; Owens JW; Freyberger A
    Arch Toxicol; 2007 Apr; 81(4):227-50. PubMed ID: 17047927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid disrupting chemicals and developmental neurotoxicity - New tools and approaches to evaluate hormone action.
    O'Shaughnessy KL; Gilbert ME
    Mol Cell Endocrinol; 2020 Dec; 518():110663. PubMed ID: 31760043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tributyltin: Advancing the Science on Assessing Endocrine Disruption with an Unconventional Endocrine-Disrupting Compound.
    Lagadic L; Katsiadaki I; Biever R; Guiney PD; Karouna-Renier N; Schwarz T; Meador JP
    Rev Environ Contam Toxicol; 2018; 245():65-127. PubMed ID: 29119384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refinement of the ECETOC approach to identify endocrine disrupting properties of chemicals in ecotoxicology.
    Weltje L; Wheeler JR; Weyers A; Galay-Burgos M
    Toxicol Lett; 2013 Dec; 223(3):291-4. PubMed ID: 23467018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
    Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
    Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to Differentiate General Toxicity-Related Endocrine Effects from Endocrine Disruption: Systematic Review of Carbon Disulfide Data.
    Printemps N; Le Magueresse-Battistoni B; Mhaouty-Kodja S; Viguié C; Michel C
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of petroleum streams for thyroid toxicity.
    Fowles JR; Banton MI; Boogaard PJ; Ketelslegers HB; Rohde AM
    Toxicol Lett; 2016 Jul; 254():52-62. PubMed ID: 27150732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine disruptors and the thyroid gland--a combined in vitro and in vivo analysis of potential new biomarkers.
    Schmutzler C; Gotthardt I; Hofmann PJ; Radovic B; Kovacs G; Stemmler L; Nobis I; Bacinski A; Mentrup B; Ambrugger P; Grüters A; Malendowicz LK; Christoffel J; Jarry H; Seidlovà-Wuttke D; Wuttke W; Köhrle J
    Environ Health Perspect; 2007 Dec; 115 Suppl 1(Suppl 1):77-83. PubMed ID: 18174954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.